Non-Hodgkin's Lymphoma

Bone Marrow Transplantation (2004) 33, 921–923. doi:10.1038/sj.bmt.1704467 Published online 22 March 2004

Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma

B Lemieux1, S Tartas1, C Traulle1, D Espinouse1, C Thieblemont1, F Bouafia1, Q Alhusein1, D Antal1, G Salles1 and B Coiffier1

1Haematology Department, Centre Hospitalier Lyon Sud, Hospices civils de Lyon – Université Claude Bernard, Pierre-Benite, France

Correspondence: Dr B Coiffier, Haematology Department, Centre Hospitalier Lyon Sud, Hospices civils de Lyon – Université Claude Bernard, Pavillon 4H, 165, chemin du Grand Revoyet, 69495 Pierre-Bénite Cedex, France. E-mail: bertrand.coiffier@chu-lyon.fr

Received 24 September 2003; Accepted 2 January 2004; Published online 22 March 2004.

Top

Abstract

Rituximab, an anti-CD20 monoclonal antibody, is increasingly used in the treatment of B-cell non-Hodgkin's lymphoma. Late-onset neutropenia in relation to rituximab has been recently described. In this report, we present six cases occurring after stem cell transplantation and discuss the potential impact of this complication.

Keywords:

non-Hodgkin's lymphoma, rituximab, autologous transplantation

Extra navigation

.

naturejobs

More science jobs
Post a job for free
ADVERTISEMENT